-
View article
#Financial publicationsInterview with Anne-Catherine Ropers - Significant full-year earnings and a transitional fourth quarter marked by the launch of the new MTP
2026/04/30 -
View article
#Financial publicationsInterview with Clotilde L’Angevin - Robust results, a controlled management framework and the strength of our capital position support our progress
2026/04/30 -
View article
#Group newsCrédit Agricole des Savoie becomes official partner of the 2027 UCI Haute-Savoie Mont-Blanc World Cycling Championships
2026/04/27
- 2010/05/06
- 3 min
- 0
-
0
Paris, 6 May 2010
Bruno Montanari has joined Crédit Agricole Private Equity as Life Sciences Investment Manager in the Venture Capital team, which is dedicated to investments in innovative companies. The Life Sciences team, under the direction of Dr. Philippe Guinot, is now comprised of four investors. The team has invested about a hundred million euros since its creation in 2002.
Bruno Montanari, age 36, holds two degrees, a PhD in pharmaceuticals from the Université René Descartes (University of Paris V) and a Masters from the Ecole des Hautes Etudes Commerciales (HEC, Paris).
He began his career in London in 1999 as an analyst for a team specialising in the pharmaceuticals sector for Deutsche Bank's investment banking arm before joining Merrill Lynch. In 2002, he was named Life Sciences Investment Director for the Paris office of CDP Capital Technology Ventures. In 2004, he joined Atlas Venture, where he was responsible for the growing portfolio of companies specialising in medical devices and drug development.
With 430 million euros under management, Crédit Agricole Private Equity's Venture Capital team invests in young companies with strong growth potential in the information technology and life sciences sectors.
Crédit Agricole Private Equity's Venture Capital team, which ranks among the most active European investors, is now comprised of 11 investment professionals.